(Q39770863)

English

Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

phase III clinical trial

0 references

0 references

Cytomegalovirus

0 references

16

object named as

Michael Boeckh

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

Genovefa Anna Papanicolaou

object named as

Genovefa A Papanicolaou

3

0 references

Francisco M. Marty

object named as

Francisco M Marty

1

0 references

Jo-Anne H. Young

object named as

Jo-Anne H Young

7

0 references

2

object named as

Per Ljungman

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

Hermann Einsele

11

object named as

Hermann Einsele

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

9

object named as

Johan Maertens

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

author name string

Drew J Winston

4

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

Roy F Chemaly

5

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

Lynne Strasfeld

6

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

Tulio Rodriguez

8

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

Michael Schmitt

10

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

Augustin Ferrant

12

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

Jeffrey H Lipton

13

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

Stephen A Villano

14

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

Hongzi Chen

15

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

Maribavir 1263-300 Clinical Study Group

17

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

publication date

21 March 2011

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

number of pages

9

1 reference

based on heuristic

inferred from page(s)

Lancet Infectious Diseases

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

284-292

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970024-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970024-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo-controlled, double-blind trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970024-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970024-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients. The Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970024-X

7 January 2021

based on heuristic

inferred from DOI database lookup

How we treat cytomegalovirus in hematopoietic cell transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970024-X

7 January 2021

based on heuristic

inferred from DOI database lookup

The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970024-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970024-X

7 January 2021

based on heuristic

inferred from DOI database lookup

In vitro activities of benzimidazole D- and L-ribonucleosides against herpesviruses

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970024-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970024-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970024-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Definitions of cytomegalovirus infection and disease in transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970024-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I dose escalation trial evaluating the pharmacokinetics, anti-human cytomegalovirus (HCMV) activity, and safety of 1263W94 in human immunodeficiency virus-infected men with asymptomatic HCMV shedding

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970024-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970024-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Plasma polymerase chain reaction for cytomegalovirus DNA after allogeneic marrow transplantation: comparison with polymerase chain reaction using peripheral blood leukocytes, pp65 antigenemia, and viral culture

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970024-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of conditioning regimen intensity on CMV infection in allogeneic hematopoietic cell transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970024-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Optimal search strategies for retrieving scientifically strong studies of treatment from Medline: analytical survey.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970024-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized comparison of oral valacyclovir and intravenous ganciclovir for prevention of cytomegalovirus disease after allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970024-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970024-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized clinical trial of ganciclovir vs acyclovir for prevention of cytomegalovirus antigenemia after allogeneic transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970024-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. European Acyclovir for CMV Prophylaxis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970024-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Antiviral prophylaxis in haematological patients: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970024-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Management of CMV, HHV-6, HHV-7 and Kaposi-sarcoma herpesvirus (HHV-8) infections in patients with hematological malignancies and after SCT.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970024-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Risk factors for cytomegalovirus infection after human marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970024-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970024-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Cytomegalovirus prophylaxis and treatment after hematopoietic stem cell transplantation in Canada: a description of current practices and comparison with Centers for Disease Control/Infectious Diseases Society of America/American Society for Blood a

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970024-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Surrogate and mediating endpoints: current status and future directions

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970024-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1473-3099(11)70024-X

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39770863&oldid=2090153095"